(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Astrazeneca's EVP – International shares how the company is working to deliver healthcare that is inclusive, impactful and ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Professional analysts at Barclays Capital have reiterated their Buy ratings on these proven UK shares, so should investors ...

AstraZeneca, a globally leading biopharmaceutical company, kicked off construction on a new small molecule drug manufacturing ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...